Page 85 - Read Online
P. 85
Byrne et al. Metab Target Organ Damage 2024;4:10 https://dx.doi.org/10.20517/mtod.2024.06 Page 7 of 7
33. Hagström H, Vessby J, Ekstedt M, Shang Y. 99% of patients with NAFLD meet MASLD criteria and natural history is therefore
identical. J Hepatol 2024;80:e76-7. DOI PubMed
34. Harrison SA, Taub R, Neff GW, et al. Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled
phase 3 trial. Nat Med 2023;29:2919-28. DOI PubMed PMC
35. Harrison S, Bedossa P, Guy C, et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N Engl J Med
2024;390:497-509. DOI PubMed
36. Mantovani A, Byrne CD, Targher G. Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor
agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review. Lancet
Gastroenterol Hepatol 2022;7:367-78. DOI PubMed
